🚚 Free shipping on all orders above $299 · 30 days money back guarantee · Helpline +1 251-332-4105

Afatinib 20 mg

$69.00$2.46 per tablet · 28 tablets

Afanat 20 mg Tablet treats non-small cell lung cancer. Buy at the best price online in the US, UK & Australia. Fast shipping available!

Choose pack sizePrice per tablet shown

Want to order in bulk / B2B price?

Tracked, discreet delivery

Ships in discreet packaging with a tracking number. Free shipping on orders above $299.

30 days money back guarantee

Damaged, missing or only part of your order arrived? Choose a new package or a full refund.

Questions before you order?

Call +1 251-332-4105 or email order@pharmeasybank.com.

SECURE CHECKOUT
DISCOVER
MasterCard
VISA

Share

What Is Afatinib 20 mg?

Afatinib 20 mg is an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor class.

It is primarily used to treat selected forms of non-small cell lung cancer (NSCLC) associated with specific mutations in the epidermal growth factor receptor (EGFR) gene.

EGFR is a protein found on the surface of many cells. It helps regulate cell growth, survival and division.

In certain cancers, mutations in the EGFR gene cause abnormal receptor activity, allowing cancer cells to grow and divide uncontrollably.

Afatinib works by irreversibly blocking the activity of several receptors belonging to the ErbB family, including EGFR (ErbB1), HER2 (ErbB2) and ErbB4.

By inhibiting these signaling pathways, afatinib interferes with signals that promote cancer cell growth and survival.

Afatinib is described as a second-generation EGFR tyrosine kinase inhibitor.

Unlike conventional cytotoxic chemotherapy, it targets specific molecular signaling pathways involved in cancer growth.

However, it can also affect normal tissues that depend on EGFR signaling, particularly the skin and gastrointestinal tract.

This explains why diarrhea, skin rash and mouth inflammation are common adverse effects.

Afatinib may be used in patients whose tumors contain susceptible EGFR mutations, depending on the approved indication, mutation type, previous treatment and available alternatives.

Important: Afatinib is not suitable for all lung cancers. Molecular testing is necessary to determine whether the tumor has an EGFR mutation for which afatinib is an appropriate treatment.

How Does Afatinib 20 mg Work?

1. Targets the ErbB Receptor Family

Afatinib inhibits several receptor tyrosine kinases belonging to the ErbB family.

These receptors participate in cellular growth and survival signaling.

2. Inhibits EGFR Activity

Certain EGFR mutations cause abnormal receptor signaling in cancer cells.

Afatinib blocks the kinase activity of susceptible EGFR receptors.

3. Forms an Irreversible Bond

Afatinib binds covalently to the kinase domains of targeted ErbB receptors.

This produces irreversible inhibition of receptor activity.

4. Suppresses Cancer Growth Signaling

Afatinib reduces signaling through pathways involved in cellular proliferation and survival.

5. Interferes With Cell Division

By blocking growth-promoting signals, afatinib can slow the proliferation of susceptible cancer cells.

6. Promotes Cancer Cell Death

In certain EGFR-dependent cancer cells, inhibition of signaling may promote apoptosis.

7. Reduces Tumor Growth

Afatinib may reduce tumor size or delay disease progression in appropriately selected patients.

8. Provides Molecularly Targeted Treatment

Its clinical activity depends substantially on the molecular characteristics of the tumor.

Uses of Afatinib 20 mg

1. EGFR Mutation-Positive Non-Small Cell Lung Cancer

Afatinib is used for selected patients with advanced or metastatic NSCLC containing susceptible EGFR mutations.

Treatment selection depends on molecular testing and current clinical guidelines.

2. EGFR Exon 19 Deletion-Positive NSCLC

Afatinib has established activity against lung cancers containing certain EGFR exon 19 deletion mutations.

However, newer EGFR-targeted therapies may be preferred in many current treatment settings.

3. EGFR L858R Mutation-Positive NSCLC

Afatinib may be used in selected patients whose tumors contain the EGFR exon 21 L858R mutation.

4. Selected Uncommon EGFR Mutations

Afatinib has activity against certain uncommon EGFR mutations, including selected G719X, L861Q and S768I mutations.

Its suitability depends on the specific mutation and applicable regulatory approval.

5. Advanced Non-Small Cell Lung Cancer

Afatinib may be prescribed for locally advanced or metastatic disease when the tumor’s molecular characteristics support its use.

6. Metastatic NSCLC

In eligible patients with metastatic NSCLC, afatinib may help control cancer growth and delay progression.

7. Previously Treated Squamous NSCLC

Afatinib has an approved indication in certain jurisdictions for metastatic squamous NSCLC that progresses after platinum-based chemotherapy.

Its current clinical role is limited and depends on available alternatives and treatment guidelines.

8. Dose-Adjusted EGFR-Targeted Therapy

The 20 mg tablet strength may be prescribed when dose reduction is needed because of treatment-related toxicity.

9. Individualized Oncology Treatment

Afatinib may be selected based on mutation status, previous treatments, patient health and anticipated adverse effects.

10. Long-Term Disease Control

When effective and tolerated, afatinib may be continued to help control cancer progression.

How to Take Afatinib 20 mg

Afatinib must be taken strictly according to the oncology specialist’s prescription.

General Administration Instructions

  1. Confirm the prescribed strength and treatment schedule.
  2. Take afatinib at approximately the same time each day.
  3. Take the medicine on an empty stomach.
  4. Avoid food for at least 3 hours before and 1 hour after taking the dose.
  5. Swallow the tablet whole with water.
  6. Do not change the dose independently.
  7. Do not take additional tablets to compensate for a missed dose.
  8. Report diarrhea, skin reactions or breathing difficulties promptly.
  9. Attend scheduled oncology appointments and laboratory tests.
  10. Follow the prescribed dose-adjustment or interruption plan if adverse effects occur.

Is Afatinib 20 mg a Standard Starting Dose?

For many approved adult NSCLC treatment regimens, 40 mg once daily is the usual starting dose.

The 20 mg strength is frequently used after dose reduction because of adverse reactions.

In selected circumstances, an oncologist may prescribe a lower initial dose.

Should Afatinib Be Taken With Food?

No. Afatinib should generally be taken on an empty stomach.

Food can reduce afatinib exposure.

Can Afatinib Be Taken Once Daily?

Afatinib is generally prescribed once daily.

The dose and schedule must follow the oncology specialist’s instructions.

Can Afatinib Be Crushed?

Afatinib tablets should generally be swallowed whole.

If swallowing is difficult, certain product instructions describe a method for dispersing the tablet in noncarbonated water.

This should only be done according to the specific manufacturer’s instructions or guidance from the oncology team.

What If a Dose Is Missed?

For standard afatinib labeling, a missed dose may be taken when remembered unless the next scheduled dose is within 12 hours.

If the next dose is within 12 hours, skip the missed dose.

Do not double the dose.

What If Too Much Afatinib Is Taken?

An overdose may cause serious adverse effects, including severe gastrointestinal and skin reactions.

Seek urgent medical advice.

How Long Does Afatinib 20 mg Take to Work?

The response to afatinib depends on the tumor’s molecular characteristics, disease burden and individual treatment response.

After Administration

Afatinib is absorbed and begins inhibiting susceptible ErbB receptor signaling.

During the First Several Weeks

Biological effects on susceptible cancer cells may occur.

During Early Treatment Assessment

Imaging studies may identify tumor shrinkage or disease stabilization.

During Continued Treatment

The oncology team evaluates whether the cancer is responding, remaining stable or progressing.

Important: Afatinib effectiveness should be evaluated through clinical assessment and imaging rather than symptoms alone.

Common Side Effects

Possible side effects include:

  • Diarrhea
  • Acne-like skin rash
  • Dry skin
  • Itching
  • Mouth sores
  • Stomatitis
  • Nausea
  • Vomiting
  • Reduced appetite
  • Weight loss
  • Nail inflammation
  • Paronychia
  • Fatigue
  • Nosebleeds
  • Eye irritation
  • Changes in liver enzyme levels

Diarrhea and skin reactions are particularly important because they can become severe and require treatment interruption or dose reduction.

Serious Side Effects

Seek urgent medical attention if any of the following occur:

  • Severe or persistent diarrhea
  • Signs of dehydration
  • Significant reduction in urine output
  • New or worsening shortness of breath
  • Persistent cough with fever
  • Severe blistering or peeling skin
  • Severe mouth inflammation
  • Yellowing of the skin or eyes
  • Severe abdominal pain
  • Sudden vision changes
  • Severe eye pain
  • Significant weakness or dizziness

Important Serious Risks

Severe Diarrhea: Afatinib can cause severe diarrhea, dehydration and electrolyte disturbances.

Dehydration and Kidney Injury: Persistent diarrhea may lead to dehydration and acute kidney injury.

Interstitial Lung Disease: Rare but potentially fatal interstitial lung disease or pneumonitis may occur.

Severe Skin Reactions: Serious dermatological reactions, including blistering and exfoliative conditions, have been reported.

Hepatotoxicity: Afatinib may cause serious liver injury, including rare fatal cases.

Keratitis: Corneal inflammation and other eye complications may occur.

Left Ventricular Dysfunction: Afatinib may affect cardiac function in some patients.

Embryo-Fetal Toxicity: Afatinib can harm a developing fetus.

Contraindications & Precautions

1. Allergy to Afatinib

Patients with known serious hypersensitivity to afatinib or formulation ingredients should not use the medicine.

2. EGFR Mutation Testing

Molecular testing is important before afatinib is selected for EGFR mutation-directed NSCLC treatment.

3. Severe Diarrhea

Afatinib-associated diarrhea may require prompt antidiarrheal treatment, hydration, dose interruption or dose reduction.

4. Dehydration

Patients with persistent diarrhea or vomiting are at risk of dehydration and kidney complications.

5. Kidney Disease

Renal function should be assessed before and during treatment as clinically indicated.

6. Liver Disease

Patients with liver impairment require careful assessment and monitoring.

7. Interstitial Lung Disease

New or worsening respiratory symptoms require immediate medical evaluation.

8. Severe Skin Reactions

Persistent or severe rash, blistering or skin peeling requires prompt assessment.

9. Eye Disorders

Patients with eye pain, redness, light sensitivity or visual changes should seek medical attention.

10. Heart Disease

Patients with cardiac risk factors may require additional monitoring.

11. Pregnancy

Afatinib can cause fetal harm and should generally be avoided during pregnancy.

12. Breastfeeding

Breastfeeding is not recommended during afatinib treatment and for the period specified in the product labeling after the final dose.

13. Fertility

Afatinib may affect reproductive health. Fertility and reproductive planning should be discussed before treatment.

14. Drug Interactions

Potential interactions include medicines affecting P-glycoprotein (P-gp), such as:

  • Rifampicin
  • Ritonavir
  • Cyclosporine
  • Certain other P-gp inhibitors
  • Certain P-gp inducers

Interaction management may require changes in administration timing, dose or treatment selection.

15. Food Interactions

Food reduces afatinib exposure.

Administration on an empty stomach is recommended.

16. Medication Adherence

Consistent dosing is important for maintaining treatment exposure.

17. Dose Reduction

Dose reduction may be necessary when clinically significant adverse reactions occur.

18. Medical Monitoring

Healthcare professionals may assess:

  • EGFR mutation status
  • Cancer stage
  • Treatment response
  • Imaging findings
  • Diarrhea severity
  • Hydration status
  • Kidney function
  • Liver function
  • Electrolyte levels
  • Skin reactions
  • Nail changes
  • Oral mucositis
  • Eye symptoms
  • Respiratory symptoms
  • Cardiac function when indicated
  • Weight changes
  • Nutritional status
  • Medication interactions
  • Need for dose interruption
  • Need for dose reduction
  • Disease progression

Potential Therapeutic Advantages

  • Targeted Anticancer Activity.
  • EGFR Tyrosine Kinase Inhibition.
  • Irreversible ErbB Receptor Inhibition.
  • Oral Tablet Formulation.
  • Once-Daily Administration.
  • Selected EGFR Mutation-Positive NSCLC Treatment.
  • Activity Against Certain Uncommon EGFR Mutations.
  • Molecularly Guided Treatment Selection.
  • Cancer Growth Signaling Inhibition.
  • Potential Tumor Growth Control.
  • Dose Adjustment Flexibility.
  • 20 mg Dose-Reduction Strength.
  • Specialist-Directed Long-Term Treatment.

Disadvantages / Limitations

  • Not Suitable for Every Lung Cancer.
  • Requires Molecular Testing.
  • May Cause Severe Diarrhea.
  • May Cause Dehydration.
  • May Cause Skin Rash.
  • May Cause Mouth Sores.
  • May Cause Nail Inflammation.
  • May Cause Reduced Appetite.
  • May Cause Weight Loss.
  • May Cause Liver Injury.
  • May Cause Kidney Complications.
  • Rare Interstitial Lung Disease Risk.
  • Potential Eye Complications.
  • Potential Cardiac Effects.
  • Pregnancy-Related Harm.
  • Requires Empty-Stomach Administration.
  • Potential Drug Interactions.
  • May Require Dose Reduction.
  • Requires Regular Oncology Monitoring.
  • Cancer May Develop Treatment Resistance.
  • Does Not Guarantee a Cure.

Important Notes

Generic Name: Afatinib.

Strength: 20 mg.

Drug Class: Tyrosine Kinase Inhibitor.

Therapeutic Category: Targeted Anticancer Medicine.

Mechanism of Action: Irreversible ErbB Receptor Tyrosine Kinase Inhibition.

Primary Indication: Selected EGFR Mutation-Positive NSCLC.

Route: Oral.

Typical Administration: Once Daily.

Food Requirement: Empty Stomach.

20 mg Strength: Commonly Used for Dose Reduction.

Major Warning: Severe Diarrhea and Dehydration.

Lung Warning: Interstitial Lung Disease Risk.

Liver Monitoring: Important.

Kidney Monitoring: As Clinically Indicated.

Pregnancy: Can Cause Fetal Harm.

Breastfeeding: Not Recommended During Treatment.

Medical Supervision: Oncology Specialist Required.

Storage: Follow Manufacturer Instructions.

Frequently Asked Questions

1. What is Afatinib 20 mg used for?

Afatinib is used to treat selected forms of advanced or metastatic non-small cell lung cancer, particularly tumors with susceptible EGFR mutations.

2. Is Afatinib 20 mg a chemotherapy medicine?

Afatinib is a targeted anticancer medicine classified as a tyrosine kinase inhibitor. It differs from conventional cytotoxic chemotherapy.

3. How does Afatinib work?

It irreversibly inhibits certain ErbB receptor tyrosine kinases, including EGFR, and interferes with cancer growth signaling.

4. Is Afatinib 20 mg used for lung cancer?

Yes. Afatinib is used in selected patients with NSCLC when the tumor characteristics and treatment history support its use.

5. Does Afatinib require EGFR testing?

EGFR mutation testing is important when selecting afatinib for mutation-directed NSCLC treatment.

6. Is Afatinib 20 mg the standard starting dose?

For many approved adult NSCLC regimens, 40 mg once daily is the usual starting dose. The 20 mg strength is commonly used for dose reduction.

7. Can Afatinib 20 mg be taken daily?

Yes. Afatinib is generally administered once daily according to the oncology prescription.

Product DetailsInformation
Product NameAfatinib 20 mg
Generic NameAfatinib
Active IngredientAfatinib
Strength20 mg
Dosage FormOral Film-Coated Tablet
Drug ClassTyrosine Kinase Inhibitor (TKI)
Therapeutic CategoryOncology / Targeted Anticancer Medicine
Primary UsesSelected EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Mechanism of ActionIrreversible Inhibition of ErbB Family Receptor Tyrosine Kinases
Route of AdministrationOral
Dosage FrequencyGenerally Once Daily, as Prescribed
Treatment DurationUntil Disease Progression or Unacceptable Toxicity, as Directed
ManufacturerDepends on Brand
Brand NameNot Specified
Pack SizeDepends on Manufacturer
Prescription StatusPrescription-Only Anticancer Medicine
StorageFollow Manufacturer Instructions
Medical SupervisionOncology Specialist Required
Pack sizes28 tablets, 56 tablets, 84 tablets
Bulk / B2B price inquiry

Tell us what you need and we’ll reply by email.